Project Grant R56DK144158
Award Date 9/12/25
Completion Date 8/31/26
Dollars Obligated $221K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Antonio, TX 78249, USA
Similar Awards
- This $3,065,252 federal Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The project aims to develop engineered metabolite-based nanoparticles for immunomodulation of macrophages to treat obesity, a critical health concern due to its links to metabolic diseases. The Terasaki Institute for Biomedical Innovation, a non-profit research...
- This Project Grant award of $307,508 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop a novel bioengineered brown adipocyte (fat cell) transplant as a potential new therapy for treating obesity and associated metabolic disorders. The award will fund research by United Biotherapeutics LLC to further develop a safer and more efficient adeno-associated...
- This $3,255,832 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) will support research at the University of Chicago to investigate the role of macrophages in weight loss-induced metabolic health and adipose tissue inflammation resolution. The project aims to determine the phenotype, function, and transcriptome of visceral and subcutaneous adipose tissue macrophages across mouse and human models, as well as test strategies like cell...
- The University of Pennsylvania was awarded a $1,418,750 Project Grant from the National Institutes of Health (NIH) Trans-NIH Research Support Program (CFDA 93.310) to conduct research on "Optogenetic Engineering of Thermogenic Adipose Tissue as a Novel Cell Therapy for Obesity." The goal of this project is to develop new treatments to increase energy expenditure and combat the public health challenge of obesity, which affects over 40% of the U.S. population. The research aims to...
- This federal Project Grant award of $803,748 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant is funding research to investigate the modulation of insulin signaling in adipocytes (fat cells) and how improved adipocyte insulin sensitivity can contribute to positive metabolic outcomes. The research team at The University of Texas Southwestern Medical...
- This $2,559,138 Project Grant award, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to define the mechanisms regulating adipose (fat) tissue metabolic memory and its role in rebound weight gain following obesity treatment. The project, led by researchers at the University of Pennsylvania, aims to: 1) determine the role of LYVE1+ macrophages in...
- This $1,021,719.00 federal Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant recipient, Emmyon, Inc., is developing a novel small molecule therapeutic (EMMY1-25) that has demonstrated the ability to promote weight loss without muscle loss and protect against dysfunction of pancreatic beta cells in mouse models of obesity and type 2...
- This $315,342 Project Grant was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), to Velum Inc., a pharmaceutical research company based in Cambridge, Massachusetts. The grant supports the development of a novel weight loss drug centered on the peptide hormone Peptide YY (PYY). The goal is to create a chimeric triagonist molecule that combines the effects of PYY...
- This $2,638,760.00 Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research aims to investigate a novel mechanism involving the metabolite rhodoquinone (RQ) and its potential role in improving mitochondrial function and mitigating metabolic diseases caused by obesity. Specifically, the project will elucidate how the RQ/fumarate...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $752,158 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Rerx Therapeutics, Inc. to develop a small molecule therapeutic to address obesity and associated metabolic disorders. The goal is to investigate the efficacy and safety of RERX-001, an orally bioavailable small molecule that targets lipid homeostasis and energy metabolism, in diet-induced...